MDGL
$441.16-13.06 (-2.88%)
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor bet...
Recent News
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge?
If you are wondering whether Madrigal Pharmaceuticals' current share price reflects its underlying worth, you are not alone. The stock has attracted attention from investors trying to work out if the recent run justifies the valuation. The shares last closed at US$432.78, with returns of 1.6% over 7 days, a 9.4% decline over 30 days, a 27.1% decline year to date, but a 29.0% return over 1 year, 76.9% over 3 years and 271.3% over 5 years. Recent news flow around Madrigal has focused on its...
2 Under-the-Radar Stocks to Buy and Hold
These biotechs are slowly making a name for themselves.